Navigation Links
Inovio Pharmaceuticals to Present at OneMedForumNY 2013 Investor Conference
Date:6/20/2013

BLUE BELL, Pa., June 20, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that CEO Dr. J. Joseph Kim will be presenting an overview of the company as part of the Small Cap Breakthrough Technologies Track at the OneMedForum investor conference taking place at the Metropolitan Club in New York City.

Inovio's Presentation
Thursday, June 27
9:40 a.m. EDT
A live and archived webcast of the presentation will be available on Inovio's homepage.

About OneMedForum

The Breakthrough Technologies Conference, a new component of the bi-annual OneMedForum, is an invitation-only event that highlights exceptional companies developing new paradigms in therapeutics, devices, or diagnostic technology. The event aims to connect investors to small-cap companies with potential for extraordinary returns within 12 months of the conference.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its synthetic consensus design approach is intended to help the immune system identify and fight cancer cells or multiple unmatched strains of a mutating virus. These proprietary synthetic vaccines, in combination with Inovio's electroporation delivery, have in humans generated best-in-class immune responses with a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused diseases, is in phase II. Other phase I and preclinical programs focus on HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended March 31, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO


'/>"/>
SOURCE Inovio Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
2. Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge Study
3. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
4. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
5. Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant to Further Develop Mass Vaccination Device
6. Inovio Collaborator ChronTech Reports Interim Phase II Clinical Study Results from ChronVac-C Vaccine for Hepatitis C Infection
7. Inovio Pharmaceuticals to Present at BioCenturys "Future Leaders in the Biotech Industry" Conference
8. Inovio Pharmaceuticals Reports 2012 Fourth Quarter and Year End Financial Results
9. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
10. Inovio Pharmaceuticals Closes $15.1 Million Offering of Common Stock and Warrants
11. Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... May 25, 2017  In response to the opioid ... Direct Relief is working with Pfizer to make up ... no cost to community health centers, free and charitable ... "Pfizer has a long-standing commitment to ... ensuring patient safety through educational activities," said Caroline ...
(Date:5/18/2017)... May 18, 2017  Two Bayer U.S. Pharmaceutical leaders ... during its recent 28 th Woman of ... event showcases HBA,s longstanding mission of furthering the advancement ... Cindy Powell-Steffen , senior director of ... division, and Libby Howe , a regional business ...
(Date:5/11/2017)... 2017  Thornhill Research Inc. ( Toronto, ... $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the ... Corporation (CCC) ( Ottawa, Ontario, Canada ... general anesthesia to patients requiring emergency medical procedures ... Marine Corps have been a longtime partner with ...
Breaking Medicine Technology:
(Date:5/29/2017)... , ... May 29, 2017 , ... ... a new training program for Recovery Coaches who are seeking opportunities to provide ... court systems, treatment centers, and others. Recovery Coaching and Professionalism© was created in ...
(Date:5/29/2017)... ... 2017 , ... Commercial door hardware needs to be safer, ... need to protect the lives of people such as employees, customers and clients ... assets and company records too. Further, businesses aren’t just protecting against strangers wishing ...
(Date:5/29/2017)... , ... May 29, 2017 , ... A New York ... a 6 month test of the effectiveness of Artificial Intelligence (AI) in helping nudge ... bad health game,’ said Wayne Hartrick, President of the Canadian Men’s Health Foundation (CMHF), ...
(Date:5/28/2017)... ... May 28, 2017 , ... Starting in May, patients at ... latest Heart Rate Variability (HRV) diagnostic test. , Nerve-Express, originally designed for the Navy ... indicating the state of a patient’s autonomic nervous system (ANS). The ANS controls ...
(Date:5/28/2017)... ... May 28, 2017 , ... Florida Pain Relief Group, ... Jorge Fernandez-Silva, M.D., has joined its new Melbourne pain clinic. , Dr. ... minimally invasive techniques to treat and manage many types of pain. , ...
Breaking Medicine News(10 mins):